LipimetiX Development Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Corporate
  • Financing Rounds
  • 2

LipimetiX Development General Information

Description

Developer of drugs for cholesterol-related diseases. The company focuses on the development of drugs for the treatment of refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride-rich lipoproteins to receptors on the liver.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • 5 Commonwealth Road
  • Suite 2A
  • Natick, MA 01760
  • United States
+1 (508) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LipimetiX Development Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LipimetiX Development‘s full profile, request access.

Request a free trial

LipimetiX Development Executive Team (2)

Name Title Board Seat Contact Info
Dennis Goldberg Ph.D President, Chairman & Co-Founder
Philip Friden Ph.D Vice President, Research & Development & Co-Founder
To view LipimetiX Development’s complete executive team members history, request access »

LipimetiX Development Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore LipimetiX Development‘s full profile, request access.

Request a free trial